Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RTRX

Travere Therapeutics (RTRX) Stock Price, News & Analysis

Travere Therapeutics logo

About Travere Therapeutics Stock (NASDAQ:RTRX)

Advanced Chart

Key Stats

Today's Range
$20.15
$21.71
50-Day Range
$24.25
$28.18
52-Week Range
$8.98
$24.96
Volume
2.33 million shs
Average Volume
412,277 shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RTRX Stock News Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Travere Therapeutics price target raised to $47 from $45 at Canaccord
Travere Therapeutics price target lowered to $27 from $31 at BofA
Travere Therapeutics price target raised to $31 from $29 at BofA
Travere Therapeutics price target raised to $44 from $42 at JPMorgan
See More Headlines

RTRX Stock Analysis - Frequently Asked Questions

Travere Therapeutics, Inc. (NASDAQ:RTRX) issued its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT).

Company Calendar

Last Earnings
11/05/2020
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RTRX
Fax
N/A
Employees
221
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-146,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$175.34 million
Price / Cash Flow
N/A
Book Value
$5.15 per share
Price / Book
4.11

Miscellaneous

Free Float
N/A
Market Cap
$1.08 billion
Optionable
Not Optionable
Beta
0.67
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:RTRX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners